Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates

Abstract

Bispecific antibodies (bsAbs) hold promises for enhanced therapeutic potential surpassing that of their parental monoclonal antibodies. However, bsAbs pose great challenges in their manufacturing, and one of the common reasons is their susceptibility to aggregation. Building on previous studies demonstrating the functionality and potential manufacturability of Fab-scFv format bsAb, this investigation delved into the impact of environmental factors—such as pH, buffer types, ionic strength, protein concentrations, and temperatures—on its stability and the reversal of its self-associated aggregates. Mildly acidic, low-salt conditions were found optimal, ensuring bsAb stability for 30 days even at elevated temperature of 40 °C. Furthermore, these conditions facilitated the reversal of its self-associated aggregates to monomers during the initial 7-day incubation period. Our findings underscore the robustness and resilience of Fab-scFv format bsAb, further confirming its potential manufacturability despite its current absence as commercial products.

Keywords

Bispecific antibody / Fab-scFv / Stability / Reversible-self association / Environmental factors

References

[1] Andersen CB, . Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci, 2010, 19(2): 279-290.

[2] Andrews JM, Roberts CJ. A Lumry−Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J Phys Chem B, 2007, 111(27): 7897-7913.

[3] Arosio P, . Aggregation stability of a monoclonal antibody during downstream processing. Pharm Res, 2011, 28(8): 1884-1894.

[4] Arosio P, . On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. Biophys Chem, 2012, 168–169: 19-27.

[5] Baek Y, . Stereospecific interactions between histidine and monoclonal antibodies. Biotechnol Bioeng, 2019, 116(10): 2632-2639.

[6] Berteau C, . Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices, 2015, 8: 473-484.

[7] Bhatta P, . Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries. Mabs, 2021, 13(1): 1859049.

[8] Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib Ther, 2021, 4(2): 73-88.

[9] Chen SW, . Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography. Bioresour Bioprocess, 2022, 9(1): 72.

[10] Chi EY, . Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res, 2003, 20(9): 1325-1336.

[11] Clarkson BR, Schön A, Freire E. Conformational stability and self-association equilibrium in biologics. Drug Discov Today, 2016, 21(2): 342-347.

[12] Cohen SI, . Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations. J Chem Phys, 2011, 135(6

[13] De Nardis C, . A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G(1). J Biol Chem, 2017, 292(35): 14706-14717.

[14] Dobson CM, Šali A, Karplus M. Protein folding: a perspective from theory and experiment. Angew Chem Int Ed Engl, 1998, 37(7): 868-893.

[15] Esfandiary R, . Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions. J Pharm Sci, 2015, 104(2): 577-586.

[16] Gentiluomo L, . Characterization of native reversible self-association of a monoclonal antibody mediated by Fab–Fab interaction. J Pharm Sci, 2020, 109(1): 443-451.

[17] Gunasekaran K, . Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem, 2010, 285(25): 19637-19646.

[18] Hari SB, . Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry, 2010, 49(43): 9328-9338.

[19] Jiskoot W, . Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo vadis?. J Pharm Sci, 2022, 111(4): 861-867.

[20] Kenrick S, Some D, Wyatt Technology Corp (2014) The diffusion interaction parameter (kD) as an indicator of colloidal and thermal stability. WP5004, Wyatt Technology Corp., Santa Barbara

[21] Klein C, . The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov, 2024, 23(4): 301-319.

[22] Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol, 2014, 15(6): 384-396.

[23] Labrijn AF, . Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov, 2019, 18(8): 585-608.

[24] Laue T. Proximity energies: a framework for understanding concentrated solutions. J Mol Recognit, 2012, 25(3): 165-173.

[25] Lee S, . Aggregation and cellular toxicity of pathogenic or non-pathogenic proteins. Sci Rep, 2020, 10(1): 5120.

[26] Li W, . Antibody aggregation: insights from sequence and structure. Antibodies, 2016, 5(3): 19.

[27] Liu J, . Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci, 2005, 94(9): 1928-1940.

[28] Loh HP, . Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies. Mabs, 2023, 15(1): 2231129.

[29] Merchant AM, . An efficient route to human bispecific IgG. Nat Biotechnol, 1998, 16(7): 677-681.

[30] Moretti P, . BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs. BMC Proc, 2013, 7(6): O9.

[31] Ong HK, . Vector design for enhancing expression level and assembly of knob-into-hole based FabscFv-Fc bispecific antibodies in CHO cells. Antib Ther, 2022, 5(4): 288-300.

[32] Pang KT, . Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics. Biotechnol Adv, 2023, 67.

[33] Panina AA, . Development of the bispecific antibody in Fab-scFv format based on an antibody to human interferon beta-1 and antibody to HER2 receptor. Russ J Bioorg Chem, 2020, 46(4): 572-581.

[34] Ridgway JBB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel, 1996, 9(7): 617-621.

[35] Roberts CJ. Non-native protein aggregation kinetics. Biotechnol Bioeng, 2007, 98(5): 927-938.

[36] Rouet R, Christ D. Bispecific antibodies with native chain structure. Nat Biotechnol, 2014, 32(2): 136-137.

[37] Saurabh S, . Understanding the stabilizing effect of histidine on mAb aggregation: a molecular dynamics study. Mol Pharm, 2022, 19(9): 3288-3303.

[38] Schermeyer MT, . Characterization of highly concentrated antibody solution—a toolbox for the description of protein long-term solution stability. Mabs, 2017, 9(7): 1169-1185.

[39] Skamris T, . Monoclonal antibodies follow distinct aggregation pathways during production-relevant acidic incubation and neutralization. Pharm Res, 2016, 33(3): 716-728.

[40] Stolzke T, Brandenbusch C. Simplified choice of suitable excipients within biologics formulation design using protein–protein interaction- and water activity-maps. Eur J Pharm Biopharm, 2022, 176: 153-167.

[41] Sudrik CM, . Understanding the role of preferential exclusion of sugars and polyols from native state IgG1 monoclonal antibodies and its effect on aggregation and reversible self-association. Pharm Res, 2019, 36(8): 109.

[42] Sule SV, . Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength. Mol Pharm, 2012, 9(4): 744-751.

[43] Sun Y, . Bispecific antibodies in cancer therapy: target selection and regulatory requirements. Acta Pharm Sin B, 2023, 13(9): 3583-3597.

[44] Surowka M, Klein C. A pivotal decade for bispecific antibodies?. Mabs, 2024, 16(1): 2321635.

[45] Suurs FV, . A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther, 2019, 201: 103-119.

[46] Svilenov HL, Winter G. Formulations that suppress aggregation during long-term storage of a bispecific antibody are characterized by high refoldability and colloidal stability. J Pharm Sci, 2020, 109(6): 2048-2058.

[47] Tapia-Galisteo A, . When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics, 2023, 13(3): 1028-1041.

[48] Tian X, . Small-angle X-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4. J Pharm Sci, 2014, 103(6): 1701-1710.

[49] Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm, 2005, 289(1–2): 1-30.

[50] Wei J, . Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol, 2022, 13: 1035276.

[51] Wood CV, . Kinetics and competing mechanisms of antibody aggregation via bulk- and surface-mediated pathways. J Pharm Sci, 2020, 109(4): 1449-1459.

[52] Xu AY, . Role of domain–domain interactions on the self-association and physical stability of monoclonal antibodies: effect of pH and salt. J Phys Chem B, 2023, 127(39): 8344-8357.

Funding

Agency for Science, Technology and Research(BMRC Central Research Fund)